Search

Particularly in highly active disease courses, we urgently need blood-based biomarkers for therapy guidance, which could include autoantibody levels, taking into account individual therapy. For example, treatment of AChR autoantibody-positive generalized MG with neonatal Fc receptor inhibitors reveals a strong correlation between clinical severity and AChR autoantibodies, as well as total immunoglobulin G (IgG) levels. Keywords: activity; autoantibody level; biomarker; myasthenia gravis EN activity autoantibody level biomarker myasthenia gravis 1162 1164 3 03/08/23 20230401 NES 230401 Dear Editor, We appreciate the comments from Li et al. [[1]] on aspects of our article entitled "Role of Autoantibody Levels as Biomarkers in the Management of Patients With Myasthenia Gravis: A Systematic Review and Expert Appraisal.". [Extracted from the article]